Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Immunotherapy

Personalized neoantigen mRNA vaccine mitigates melanoma recurrence

Nature Reviews Clinical Oncology volume 21, page 168 (2024)Cite this article

Subjects

Access through your institution
Buy or subscribe

Various immune-checkpoint inhibitors are approved as adjuvant therapies for high-risk melanoma (stage IIB–IV), but disease recurrence remains common. Now, new data indicate that the personalized therapeutic vaccine mRNA-4157 (V940) improves disease control when added to adjuvant pembrolizumab.

In the phase IIb KEYNOTE-942 trial, 157 patients with completely resected stage IIIC–IV melanoma were randomly assigned (2:1) to receive up to 18 doses of pembrolizumab with or without up to 9 doses of V940. V940 is a nanoparticle-encapsulated individualized mRNA sequence that encodes up to 34 neoantigens identified in each patient through bioinformatic analysis of whole-exome-sequencing, RNA-sequencing and HLA-profiling data. Recurrence-free survival (RFS), using a two-sided P value threshold of <0.198, was the primary end point.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence. Nat Rev Clin Oncol 21, 168 (2024). https://doi.org/10.1038/s41571-024-00867-1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-024-00867-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer